Find clinical trials for Adenocarcinoma in London, England
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Adenocarcinoma trials near London, England, GBR:
with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...
Phase 3
London, United Kingdom and 155 other locations
(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...
Phase 3
London, London, City of, United Kingdom and 167 other locations
(CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...
Phase 3
London, United Kingdom and 229 other locations
participants to treat locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEA).T...
Phase 2
London, Greater London, United Kingdom and 46 other locations
resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease....
Phase 2
London, United Kingdom and 69 other locations
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...
Phase 3
London, United Kingdom and 124 other locations
and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...
Phase 2
London, United Kingdom and 43 other locations
with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma...
Phase 2, Phase 3
London, London, City of, United Kingdom and 158 other locations
in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ) adenocarcinoma...
Phase 2
London, United Kingdom and 8 other locations
This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection comp...
Phase 3
Cambridge, United Kingdom and 74 other locations
Clinical trials
Research sites
Resources
Legal